Edwards Lifesciences Corp 8-K

What Happened
Edwards Lifesciences Corporation announced via an 8-K (Regulation FD disclosure) that on January 9, 2026 the U.S. District Court for the District of Columbia granted the U.S. Federal Trade Commission’s motion for an injunction blocking Edwards’ proposed acquisition of JenaValve Technology, Inc. As a result, Edwards will not acquire JenaValve. A press release dated January 9, 2026 was attached as Exhibit 99.1 to the filing.

Key Details

• Press release dated January 9, 2026; 8-K filed with the SEC (Regulation FD disclosure).
• Court: U.S. District Court for the District of Columbia granted the FTC’s motion for an injunction.
• Target company: JenaValve Technology, Inc. (the proposed acquisition is blocked).
• Immediate outcome: Edwards will not complete the acquisition of JenaValve.

Why It Matters
This filing confirms the proposed acquisition will not occur due to a court-ordered injunction prompted by the FTC. For investors, that means previously announced strategic or pipeline changes tied to the JenaValve deal will not proceed as planned; the company’s M&A outlook, product strategy, and use of capital could be affected. Shareholders should watch for further disclosures from Edwards regarding strategic alternatives, capital allocation, or impacts to clinical/product plans.